Takeda's talks to acquire Valeant's Salix stall: sources

(Reuters) - Takeda Pharmaceutical Co Ltd's negotiations to acquire Valeant Pharmaceuticals International Inc's Salix stomach-drug business have stalled over price disagreements, people familiar with the matter said on Wednesday. Shares of Valeant were down more than 8 percent at $15.71 on Wednesday after the Wall Street Journal reported that the talks had broken down. A deal for Salix would help Valeant trim the large debt pile it accumulated through aggressive acquisitions.